- Research article
- Open Access
Gene expression profiling reveals effects of Cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7
© Gaube et al; licensee BioMed Central Ltd. 2007
- Received: 25 January 2007
- Accepted: 20 September 2007
- Published: 20 September 2007
Extracts from the rhizome of Cimicifuga racemosa (black cohosh) are increasingly popular as herbal alternative to hormone replacement therapy (HRT) for the alleviation of postmenopausal disorders. However, the molecular mode of action and the active principles are presently not clear. Previously published data have been largely contradictory. We, therefore, investigated the effects of a lipophilic black cohosh rhizome extract and cycloartane-type triterpenoids on the estrogen receptor positive human breast cancer cell line MCF-7.
Both extract and purified compounds clearly inhibited cellular proliferation. Gene expression profiling with the extract allowed us to identify 431 regulated genes with high significance. The extract induced expression pattern differed from those of 17β-estradiol or the estrogen receptor antagonist tamoxifen. We observed a significant enrichment of genes in an anti-proliferative and apoptosis-sensitizing manner, as well as an increase of mRNAs coding for gene products involved in several stress response pathways. These functional groups were highly overrepresented among all regulated genes. Also several transcripts coding for oxidoreductases were induced, as for example the cytochrome P450 family members 1A1 and 1B1. In addition, some transcripts associated with antitumor but also tumor-promoting activity were regulated. Real-Time RT-PCR analysis of 13 selected genes was conducted after treatment with purified compounds – the cycloartane-type triterpene glycoside actein and triterpene aglycons – showing similar expression levels compared to the extract.
No estrogenic but antiproliferative and proapoptotic gene expression was shown for black cohosh in MCF-7 cells at the transcriptional level. The effects may be results of the activation of different pathways. The cycloartane glycosides and – for the first time – their aglycons could be identified as an active principle in black cohosh.
- Unfold Protein Response
- Aryl Hydrocarbon Receptor
- Black Cohosh
- Cimicifuga Racemosa
Cimicifuga racemosa (L.) NUTT. (syn. Actaea racemosa; black cohosh, family Ranunculaceae) is a North American perennial herb which has been traditionally used by Native Americans for the treatment of rheumatism, dyspepsia, epilepsy, kidney ailments, dysmenorrhoea and the relief of pain during menses and childbirth [1, 2]. Since the 1950s, phytopharmaceuticals containing black cohosh extracts from the rhizome are used for the alleviation of menopausal disorders . Since the Women's Health Initiative (WHI) described adverse effects of hormone replacement therapy (HRT) such as increased risk of breast cancer and cardiovascular diseases , the popularity of herbal alternatives such as black cohosh has considerably increased.
The phytochemicals in black cohosh rhizomes have been well studied, and numerous cycloartane-type triterpene glycosides (e.g. actein Figure 1), aromatic acids (e.g. caffeic and ferulic acid), cinnamic acid esters (e.g. fukinolic acid, cimicifugic acids) and various minor compounds have been reported [1, 2, 5]. The pharmacology of rhizome extracts has been investigated, whereby most investigations addressed the effects on the hormonal (estrogenic) system. An estrogen-like activity was reported initially [6–8], but these effects could not be confirmed in later studies [8–11]. Subsequently, antiestrogenic properties were proposed on the basis of in vitro experiments [8, 12, 13]. Because a black cohosh extract influenced bone, endometrium and hypothalamus, but not uterus in a estrogen-like manner, it was postulated to contain compounds that act as selective estrogen receptor modulators (SERMs) and, therefore, to be different from common phytoestrogens – a presumption that is still a matter of dispute [14–17].
In binding studies black cohosh extracts showed no affinity to estrogen receptors α and β (ERα/β), progesterone (PR) or androgen receptor (AR) [10, 16, 18, 19], but weak affinity towards the aryl hydrocarbon receptor (AhR) [20, 21]. Most recently, treatment of human breast cancer MCF-7 cells with black cohosh extracts and with fractions containing cycloartane glycosides and cinnamic acid esters, respectively, resulted in antiproliferative effects and induction of apoptosis [22, 23]. Incubation of MCF-7 cells with a fraction containing the cycloartane glycosides led to cell cycle arrest at the G1/S- and, to a lesser degree, at the G2/M-transition points, and treatment with actein affected expression levels of some proteins, such as p21, in a G1-arresting manner .
Finally, irrespective of the putative estrogenic activity recent investigations reporting dopaminergic [16, 25], serotoninergic [26, 27] and opioidic action  of black cohosh extracts provide evidence, that the beneficial effects such as reduction of hot flashes may be due to neurotransmitter and CNS activity.
Despite all these studies, the mode of action of black cohosh extracts and the nature of the active principles are presently not clear.
Rhizomes of black cohosh (Cimicifugae racemosae rhizoma) were obtained from Caesar&Loretz (Hilden, Germany, lot number 82044149). Powdered rhizome (0.5 mm particle size, 10 g) were subjected to pressurized liquid extraction using an ASE®200 Accelerated Solvent Extractor (Dionex, Sunnyvale, CA) at 120 bar and 70°C. After a preheating step (5 min), the sample was defatted with petroleum ether (5 min), followed by extraction with dichloromethane for 10 min. Solutions were collected in different vials. The petroleum ether solution was discarded. After evaporation of the solvent, 350 mg of dry dichloromethane extract was obtained.
The mixture of cycloartenol aglycons was obtained as follows: A dichloromethane extract of black cohosh rhizome (2 kg) was prepared by maceration at room temperature for 24 h. The extract (25.5 g) was separated on a silica gel column (40–63 μm, 70 × 5 cm i.d.) using a step gradient of CHCl3-MeOH-H2O (90:9.5:0.5), CHCl3-MeOH-H2O (70:30:3) and methanol. Fractions were combined on the basis of their TLC pattern. Fractions containing cycloartane glycosides were combined in equal proportions (250 mg each) and dissolved in methanol. After addition of 1 N HCl, the solution was refluxed for 1 h. Aglycons were extracted by partitioning with chloroform. The chloroform extract was evaporated to dryness, and the residue (340 mg) was purified by chromatography on a Sephadex® LH20 (Pharmacia, Uppsala, Sweden) column, eluted with methanol to afford 120 mg of aglycon mixture.
Actein was purchased from Phytoplan (Heidelberg, Germany), 17β-estradiol from Sigma-Aldrich (Taufkirchen, Germany) and tamoxifen from MP Biomedicals (Eschwege, Germany).
For subsequent experiments extract and compounds were dissolved in dimethyl sulfoxide (DMSO) and diluted with appropriate assay media. The final concentration of DMSO did not exceed 0.1%. This concentration was also used for control experiments.
The human breast adenocarcinoma cell line MCF-7 (obtained from ATCC) was routinely cultured in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (FBS) and Penicillin/Streptomycin (100 U/100 μg/ml) (Biochrom, Berlin, Germany) in a humidified incubator at 37°C and 5% CO2. Before reaching confluence, cells were splitted every 3–4 days in a 1:4- to 1:6-ratio. All experiments were performed with cells at passage numbers 25–33.
Hormone-free charcoal-dextran stripped serum (CSS) was prepared from FBS by agitating with 0.5% charcoal (Norit A) (Serva Feinbiochemica, Heidelberg, Germany) and 0.05% Dextran-T70 (Pharmacia) at 37°C for 60 min. After centrifugation at 3500 rpm CSS was filter-sterilized (0.22 μm) twice and stored at -20°C.
MCF-7 cells were seeded in 96-well microtitre plates (Greiner Bio-One, Frickenhausen, Germany) with a density of 3500 cells per well under culture conditions and incubated at 37°C and 5% CO2. After 24 hours medium was removed, cells were washed with phosphate-buffered saline (PBS), and phenol red-free DMEM (Gibco™, Invitrogen, Karlsruhe, Germany) supplemented with 10% CSS and test substances in concentrations indicated in the text were added. Medium was exchanged after 72 hours. After 120 hours cells were quantified by MTT assay [29, 30] as follows. Medium was removed and 100 μl MTT (Fluka, Buchs, Switzerland), dissolved in phenol red-free DMEM at 0.5 mg/ml, were added to each well. The plates were incubated at 37°C and 5% CO2 for 4 hours. Formazan crystals were solubilized by addition of 100 μl of 20% sodium dodecylsulfate (SDS) in H2O followed by incubation overnight at 37°C. Optical density was measured at 544 nm using a microplate reader (Galaxy FluoStar, BMG Labtechnologies, Offenburg, Germany) with background substraction. Relative proliferation values were calculated as percentage of negative control (0.1% DMSO value = 100%). Experiments were repeated at least three times with 4 to 6 replicates per test concentration. The results are given as mean value ± standard deviation (SD). Data were analyzed by Student's t-test. Statistically significance vs. DMSO control is represented as *(p < 0.05), **(p < 0.01) or ***(p < 0.001).
The acute cytotoxic potential of black cohosh extract, actein and the aglycons was determined with the Cytotoxicity Detection Kit (LDH) (Roche Diagnostics, Mannheim, Germany). No acute cytotoxicity could be found for the extract at concentrations of up to 70 μg/ml, and up to 100 μM for actein and the aglycons, respectively.
MCF-7 cells were seeded in 75 cm2 culture flasks (Greiner Bio-One) at a density of 20000 cells/cm2 under culture conditions and incubated at 37°C and 5% CO2. After 20 hours medium was removed and cells were washed with PBS. Phenol red-free DMEM containing 10% CSS and 0.1% DMSO, 15 μg/ml black cohosh extract, 20 μM actein, 30 μM aglycons, 1 nM 17β-estradiol or 10 μM tamoxifen, respectively, were added. Cells were incubated for 24 hours at 37°C and 5% CO2. Cells were washed twice with PBS and total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) including on column DNase digestion according to the standard protocol. Quantity and purity of the obtained total RNA samples were determined by UV spectroscopy. RNA quality was controlled by gel electrophoresis on 1.5% agarose, stained with ethidium bromide (1 μg/ml). RNA was stored at -80°C until use.
Total RNA from each sample was labelled and hybridized to an Affymetrix GeneChip® Human Genome U133 Plus 2.0 array (Affymetrix, Santa Clara, CA) according to the manufacturer's protocol (manual version 700217 rev 3), with minor modification. Briefly, 5 μg of total RNA was converted into cDNA by using the T7-(dT)24 Primer (Affymetrix Inc), T4gp32 (USB Corporation, Cleveland, OH) and the SuperScript II reverse transcriptase for cDNA synthesis (Invitrogen). Double-stranded cDNA was synthesized, cleaned and extracted with phenol/chloroform, followed by ethanol precipitation. Resulting cDNA was resuspended in 12 μl RNase-free water. From the ds-cDNA template biotin-labeled cRNA was made with the Enzo High Yield RNA Transcript labeling kit (Enzo Diagnostics, Farmingdale, NY). The labeled cRNA was purified following the Qiagen RNeasy Clean up protocol (Qiagen) and concentrated to 24 μl by ethanol precipitation. Fragmentation of the biotinylated cRNA (20 μg) was done directly before hybridization to the microarray. Hybridizations and scanning were performed at the Affymetrix GeneChip Core facility of the Medical Faculty, University of Leipzig. On-chip labeling was done with phycoerythrin-conjugated streptavidin. After final washing steps fluorescence was detected with the Affymetrix GeneChip 3000 7G scanner.
Primary data analysis
Initial data analysis was performed using the Affymetrix Microarray Suite v5.1 software, setting the scaling of all probe sets to a constant value of 500 for each GeneChip. Because of the better implemented normalisation algorithm data were further normalized using RMA-Express software [31–33]. With RMAExpress all arrays were visually checked. There were no obvious failures on the chips. RMAExpress is using an enhanced quantile normalization [31, 32]. All 8 experiments (4 different treatments – black cohosh extract, estradiol, tamoxifen and DMSO – in duplicate) were normalized together. Data were then exported to MS-Excel sheets. We used both the log as well as the natural output. All further comparisons and analyses are based on these RMAExpress outputs. Clearly regulated (= differentially expressed) genes were determined using the following criteria: (I) The signal intensity is higher than the median of all signal intensities on the array and (II) in both independent duplicate experiments the fold change vs. DMSO control is larger than 1.5.
Primers used for real-time RT-PCR
Primer Sequence 5'-3'
Baculoviral IAP repeat-containing 5 (BIRC5)
Cyclin E2 (CCNE2)
Cyclin G2 (CCNG2)
Cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1)
Cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1)
DNA-damage-inducible transcript 4 (DDIT4)
DnaJ (Hsp40) homolog, subfamily B, member 9 (DNAJB9)
E2F transcription factor 2 (E2F2)
Estrogen receptor, alpha (ESR1)
GREB1 protein (GREB1)
Growth arrest and DNA-damage-inducible, alpha (GADD45A)
Metastasis associated in lung adenocarcinoma transcript 1 (MALAT-1)
Proliferating cell nuclear antigen (PCNA)
Vascular endothelial growth factor (VEGF)
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Gene expression microarray analysis with black cohosh extract
For gene expression profiling MCF-7 cells were treated with 15 μg/ml black cohosh extract, 1 nM 17β-estradiol, 10 μM tamoxifen or DMSO control for 24 h in the presence of 10% charcoal stripped serum. After RNA extraction, gene expression profiles were recorded using Affymetrix HG U133 Plus 2.0 GeneChip Arrays as described. Regulated (differentially expressed) genes were identified using the following selection criteria: minimal signal intensity > median and fold change vs. control > 1.5 in two independent experiments. With these criteria we identified 544 probe sets (~1% from the more than 54000 probe sets on the HG U133 Plus 2.0 Array) representing 431 genes regulated by the extract. The false positive rate with the criteria used is about 5% based on random permutation analysis of the gene expression results, showing a mean of 22 to 32 regulated probe sets (22/544 ~ 4.0%; 32/544 ~ 5.9%).
Regulation of 13 genes representing the 6 functional categories, apoptosis, proliferation, general growth, signaling & transport, metabolism and others, were verified by real-time RT-PCR from independent samples to confirm the regulation of genes connected to the major cellular effects observed.
List of selected genes regulated by black cohosh extract in MCF-7 cells. Genes are listed with symbol, GenBank accession number and fold changes vs. DMSO control of two independent microarray experiments. Genes in bold are associated to stress response. Those written in italics have been verified by real-time RT-PCR. A full list with all 431 genes is available [see Additional file 1].
DNA-damage-inducible transcript 4
P8 protein (candidate of metastasis 1)
Tumor protein p53 inducible nuclear protein 1
Tumor necrosis factor receptor superfamily, member 10b
Immediate early response 3
BCL2/adenovirus E1B 19 kda interacting protein 3-like
Baculoviral IAP repeat-containing 5 (survivin)
Growth differentiation factor 15
Vascular endothelial growth factor
DNA-damage-inducible transcript 3 (CHOP-10, GADD153)
RAS, dexamethasone-induced 1
Growth arrest and DNA-damage-inducible, alpha
Cyclin-dependent kinase inhibitor 1A (p21, Cip1)
Forkhead box O3A
Cyclin B1 interacting protein 1
Cyclin-dependent kinase 7
S-phase kinase-associated protein 2 (p45)
Chromatin assembly factor 1, subunit A (p150)
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase
E2F transcription factor 2
Kinetochore protein Spc24
Proliferation-related Ki-67 antigen
E2F transcription factor 7
Kinesin family member 11 (Eg5)
DNA replication, repair and synthesis
Recq protein-like 4
Cyclin-dependent kinase 2
Minichromosome maintenance deficient 3 (S. Cerevisiae)
CDC6 cell division cycle 6 homolog (S. Cerevisiae)
DNA replication factor
BRCA1 interacting protein C-terminal helicase 1
Minichromosome maintenance deficient 5, cell division cycle 46 (S. Cerevisiae)
Minichromosome maintenance deficient 7 (S. Cerevisiae)
Ubiquitin-like, containing PHD and RING finger domains, 1
Thymidine kinase 1, soluble
Proliferating cell nuclear antigen
Replication factor C (activator 1) 3, 38 kda
Minichromosome maintenance deficient 2, mitotin (S. Cerevisiae)
DNA replication complex GINS protein PSF2
Flap structure-specific endonuclease 1
Minichromosome maintenance deficient 4 (S. Cerevisiae)
ASF1 anti-silencing function 1 homolog B (S. Cerevisiae)
Chromosome 1 open reading frame 24
DnaJ (Hsp40) homolog, subfamily C, member 10
DnaJ (Hsp40) homolog, subfamily B, member 9
Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1
MAP kinase-interacting serine/threonine kinase 2
Eukaryotic translation initiation factor 4E binding protein 1
Stress 70 protein chaperone, microsome-associated, 60 kda
Eukaryotic translation initiation factor 2-alpha kinase 3 (syn. PERK)
Microtubule-associated protein 1 light chain 3 beta
F-box only protein 11
Ubiquitin protein ligase E3 component n-recognin 1
Heat shock 70 kda protein 5 (glucose-regulated protein, 78 kda)
Transducin (beta)-like 1X-linked
Ubiquitin specific protease 3
Eucaryotic translation initiation factor 1
SUMO1/sentrin specific protease 6
APG12 autophagy 12-like (S. Cerevisiae)
Ubiquitin-fold modifier 1
Heat shock 70 kda protein 2
F-box only protein 5 (early mitotic inhibitor 1)
Ubiquitin-conjugating enzyme E2C
Basic helix-loop-helix domain containing, class B, 2
Trinucleotide repeat containing 9
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
CCAAT/enhancer binding protein (C/EBP), beta
CCAAT/enhancer binding protein (C/EBP), gamma
Junction-mediating and regulatory protein
Endothelial PAS domain protein 1 (Hypoxia-inducible factor 2, alpha)
Nuclear factor (erythroid-derived 2)-like 2
Activating transcription factor 3
Activating transcription factor 4
Early growth response 1
Nuclear factor (erythroid-derived 2)-like 1
Chromobox homolog 4 (Pc class homolog, Drosophila)
Kruppel-like factor 4 (gut)
Zinc finger protein 36, C3H type-like 2
Cell organization, adhesion & structure and cytoskeleton
Decay accelerating factor for complement (CD55, Cromer blood group system)
Ras homolog gene family, member B
SIGNALING AND TRANSPORT
Receptors & Signal transduction
Unc-5 homolog B (C. Elegans)
TRAF family member-associated NFKB activator
Interferon gamma receptor 1
Mitogen-inducible gene 6
Ras association (ralgds/AF-6) domain family 3
Aryl hydrocarbon receptor
Tribbles homolog 1 (Drosophila
Tribbles homolog 3 (Drosophila)
Aryl hydrocarbon receptor nuclear translocator-like
Casein kinase 1, gamma 3
Hypoxia-inducible factor 1, alpha subunit
c-Jun N-terminal kinase 1 (mitogen-activated protein kinase 8, MAPK8)
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide
Estrogen receptor, alpha
Solute carrier family 7, (cationic amino acid transporter, y+ system) member 11
Potassium voltage-gated channel, Isk-related family, member 4
Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5
Solute carrier family 38, member 2
Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4
Cytochrome P450, family 1, subfamily A, polypeptide 1
Aldo-keto reductase family 1, member C1 (20-alpha (3-alpha)-hydroxysteroid dehydrogenase)
Aldehyde dehydrogenase 1 family, member L2
Cytochrome P450, family 1, subfamily B, polypeptide 1
Heme oxygenase (decycling) 1
5-Methyltetrahydrofolate-homocysteine methyltransferase reductase
Methylene tetrahydrofolate dehydrogenase (NAD+ dependent)
Cytochrome P450, family 51, subfamily A, polypeptide 1 (Sterol 14-alpha-demethylase)
Farnesyl-diphosphate farnesyltransferase 1 (Squalene synthase)
3-Hydroxy-3-methylglutaryl-Coenzyme A reductase
Acyl-coa synthetase long-chain family member 1
Phosphoenolpyruvate carboxykinase 2 (mitochondrial)
Metastasis associated in lung adenocarcinoma transcript 1
S100 calcium binding protein P
Gastric-associated differentially-expressed protein YA61P, drug sensitive protein 1
Hypothetical protein LOC222171
Brain expressed X-linked 2
Myozenin 2 (calcisarcin 1)
WD40 repeat protein Interacting with phosphoinositides of 49 kda
SLIT and NTRK-like family, member 6
In addition to the regulation of genes involved in proliferation control, we also observed regulation of apoptosis-linked genes in a pro-apoptotic manner, indicating that the extract could sensitize breast cancer cells for apoptotic events. An increase in apoptotic events would also contribute to the decrease in cellular proliferation observed. In cells treated with black cohosh the transcript of the apoptosis inhibitor survivin (baculoviral IAP repeat-containing 5, BIRC5) was downregulated, whereas genes coding for apoptosis-inducing and -supporting products (BNIP3L, TNFRSF10B, TP53INP1) were increased. FOXO3A, GADD45A, GDF 15 (growth differentiation factor 15) and p21cip 1, whose mRNA levels increased, are also connected with apoptosis in addition to their role in cell cycle control. Transcript of tyrosyl-tRNA synthetase (YARS), whose secretion is linked to apoptotic events , was upregulated. Downregulation of lymphoid-specific helicase (HELLS), as observed in our experiments, has been reported to be associated with apoptosis . The upregulation of c-Jun N-terminal kinase 1 (JNK1 = MAPK8) and DNA-damage-inducible transcript 3 (DDIT3 = CHOP = GADD153), as observed in our experiments, have been reported as related to stress-induced apoptosis [41, 42]. p8 Protein (p8), immediate early response 3 (IER3) and DNA-damage inducible transcript 4 (DDIT4, also known as REDD1 or RTP801), whose transcript was strongly upregulated, are known to be expressed under cellular stress (described later) and have been associated with both pro- and anti-apoptotic events [43–46].
Furthermore, we observed regulation of genes related to endoplasmic reticulum stress response (unfolded protein response, UPR), which involves the activation of three different pathways. Transcription of c-Jun N-terminal kinase 1 (JNK1 = MAPK8) was upregulated in our experiment. JNK1 is a target of one UPR-pathway and its activation may lead to apoptosis [42, 55]. Phosphorylation of eukaryotic translation initiation factor 2 α (eIF2α) at Ser51 is involved not only in UPR but also in responses to hypoxia, nutrient deprivation and other cellular stresses. Hence, this evolutionarily conserved pathway has been termed the integrated stress response (ISR) [41, 52]. PERK (EIF2AK3, eukaryotic translation initiation factor 2-alpha kinase 3), whose mRNA-level was increased by black cohosh treatment, is a kinase linking hypoxia stress reponse and UPR to eIF2α-phosphorylation, whereas amino acid and glucose starvation response acts via GCN2 kinase. As a consequence of eIF2α-phosphorylation the translation of most mRNAs is inhibited, but paradoxically the translation of activating transcription factor 4 (ATF4) is increased. We observed an upregulation of the ATF4 gene as well as various ATF4-induced downstream target genes, e.g. ASNS (asparagine synthetase), ATF3 (activating transcription factor 3), CHOP, GADD45A, HERPUD1 (homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1), HSPA5 (heat shock 70 kDa protein 5). Gene products of these transcripts are involved in cell survival and tumorigenesis as well as apoptotic events [42, 49, 56].
In the context of mis- or unfolded protein response some other processes of protein turnover are affected by black cohosh extract. The expression levels of various ubiquitin cycle-related genes (FBOX5, FBOX11, MAP1LC3B, SENP6, TBL1X, UBE2C, UBR1, Ufm1, USP3) were influenced by black cohosh. Some of these transcripts code for products involved with cell cycle progression and were regulated in a cell cycle arresting manner, emphasizing our results described above. Inhibitory CCNB1IP1 was upregulated, whereas SKP2 (S-phase kinase-associated protein 2; p45) and UHRF1 (Ubiquitin-like, containing PHD and RING finger domains, 1) were downregulated. Furthermore, mRNA-levels of eight different aminoacyl-tRNA synthetases (CARS, EPRS, GARS, IARS, MARS, SARS, WARS, YARS) were upregulated.
In response to black cohosh treatment, transcripts of several oxidoreductases involved with metabolism of xenobiotics were affected. In some cases we observed strong induction. The most prominent upregulation of all Cimcifuga regulated genes occurred for CYP1A1 (cytochrome P450, family 1, subfamily A, polypeptide 1). In the microarray experiments the increase was 12.4 and 3.5 fold, while RT-PCR gave even higher changes (28.5 ± 14.0 fold, p < 0.01 and 19.2 ± 10.9 fold, p < 0.05). This was accompanied by a marked but lower increase of CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1). Both enzymes are known to be activated by xenobiotics through the aryl hydrocarbon receptor pathway. Transcript of heme oxygenase 1 (HMOX1), an essential enzyme in heme catabolism and a direct target of HIF1 (see stress response), was also upregulated. Finally, transcripts of several enzymes of the cholesterol biosynthesis pathway (CYP51A1, FDFT1, HMGCR, SC4MOL, SC5DL) were marginally increased.
Interestingly, transcription of the aryl hydrocarbon receptor (AhR) which regulates expression of the CYPs, was also increased. Furthermore, we observed a downregulation of the estrogen receptor α gene (ESR1). This regulation has already been reported in response to hypoxic stress . mRNAs coding for interferon gamma receptor 1 (IFNGR1) appeared to be upregulated. The latter promotes effects of interferon γ, whose antitumor activity has previously been reported .
Within this category, two tumor-associated transcripts showed largest upregulation. MALAT-1 (metastasis in lung adenocarcinoma transcript 1), a recently identified noncoding RNA, has been shown to be activated in early-stage lung cancer. High-level expression is associated to low survival rates of patients due to high risk to develop metastatis . S100P (S100 calcium binding protein P) was reported as marker of breast cancer initiation. Expression of S100P as well as FTH1 (Ferritin H), an iron-binding protein, whose transcript was also upregulated by black cohosh, is associated to immortalization and transformation of breast epithelial cells .
Comparison of the expression pattern of black cohosh with tamoxifen and E2
Effects of actein and the cycloartane aglycon mixture
We performed the first gene expression profiling experiment with rhizomes of Cimicifuga racemosa (black cohosh) to identify molecular effects in the human breast cancer cell line MCF-7. In initial experiments analyzing cell proliferation we observed growth inhibition in response to treatment with a lipophilic extract of black cohosh, the major cycloartane-type triterpene glycoside actein and a cycloartane aglycon mixture. IC50 values were comparable to previously reported results [22–24].
Effects of a black cohosh extract on gene expression in MCF-7 cells were determined by means of Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays, enabling almost complete analysis of the transcriptome. After treatment of MCF-7 cells for 24 h with the black cohosh extract at the IC50 concentration (15 μg/ml) changes of the expression levels of 431 genes were detected using highly stringent selection criteria. Random permutation of gene expression profiles showed a mean of 22 to 32 regulated probe sets in our data set with our selection criteria indicating a false positive rate of about 5%.
Comparing the expression patterns, action of black cohosh is opposite to estradiol and more similar to tamoxifen regarding proliferation and cell survival. However, the effect of black cohosh treatment appears more complex, as significantly more genes were regulated than either with E2 or tamoxifen. The genes regulated by black cohosh did not include well-known estrogen-regulated genes, with the exception of ESR1 (the estrogen recptor α gene) and VEGF which both could be regulated via hypoxia response. In contrast, a wider range of cellular pathways and targets were affected by black cohosh but not E2 or tamoxifen. Hence, action of black cohosh in MCF-7 cells seems to be neither estrogenic nor antiestrogenic but rather multifacetted. Because MCF-7 is a model for determining estrogenic or antiestrogenic effects, we can conclude that the benefical effects of black cohosh in alleviating postmenopausal complaints might be rather due to central nervous action via dopamine, serotonin or μ opioidic receptors.
Among all regulated genes, those related to the functional categories of proliferation (cell cycle and DNA replication) and stress response (including members of different functional categories) were found to be highly significantly overrepresented, and these groups appear to be interconnected. Given that many genes were regulated at a lower level and, therefore, excluded by the stringent filter setting, a statistically highly significant accumulation of genes in these functional categories emphasizes the significance of our results.
The cell cycle inhibition observed in the proliferation experiments appears to be due to an arrest at both G1/S- and G2/M-transition points, as indicated by an accumulation of regulated genes. This finding is corroborated by recent results of a flow cytometric analysis . Several genes involved in apoptosis appeared to be regulated, most genes in a pro-apoptotic manner. Some genes are related to apoptotic as well as anti-apoptotic events. These genes are linked to different cellular stress response mechanisms. Altogether, the expression levels of approximatively 40 genes related to stress response were affected by black cohosh. Given the fact that results of stress response pathways are contradictory, pro- and anti-apoptotic gene expression may not be surprising. The main purpose of stress response is an adaptation of the cells to stress factors, resulting in cell survival, angiogenesis and promoted tumor growth. However, when stress reaches a certain threshold, the protecting pathways become saturated and cells undergo apoptosis . This may explain the seemingly contradictory effects observed in our experiment. Altogether, pro-apoptotic signalling seems to outweigh. Stress response regulation has already been previously reported for other xenobiotics such as the cancer chemoprotective phytochemical indole-3-carbinol (I3C) and its physiological condensation product diindolylmethane (DIM), whose antitumor activity has been widely investigated . Its influence on gene expression in different tumor cells – among others in breast cancer cells such as MCF-7 – shows a certain similarity to our results with black cohosh. However, the mechanism of induced stress response by I3C is still unknown.
In association with unfolded protein response various transcripts of protein turnover were affected by black cohosh. Regulation of several transcripts whose products are involved in ubiquitinylation may be due to augmented degradation of malformed proteins. Increased mRNA levels of not less than eight different aminoacyl-tRNA synthetases (ARSs) are not only linked to protein synthesis. Some ARSs are rather multifunctional proteins involved in different cellular processes . For example, the secretion of tyrosyl-tRNA synthetase (YARS) is linked to apoptotic events  and tryptophanyl-tRNA synthetase (WARS) has been shown to possess angiostatic and proliferation-inhibitory activity .
As response to exposure to black cohosh extract a group of transcripts coding for enzymes with oxidoreductase activity was upregulated ("response to xenobiotics"). A strong upregulation was observed for CYP1A1, and, to a somewhat lesser extent, of CYP1B1. Apart from well-known involvement in xenobiotic metabolism, thereby mediating toxic and tumorigenic effects of several chemicals, these two oxidoreductases are involved in the metabolism of 17β-estradiol . CYP1A1 metabolizes E2 to non-carcinogenic 2-hydroxy-E2 whereas CYP1B1 is responsible for the formation of carcinogenic 4-hydroxy-E2. The two enzymes are not always expressed at the same level in tissues. An increased production of 2-hydroxy-E2 relative to 4-hydroxy-E2, due to a higher expression level of CYP1A1 than CYP1B1, has been suggested to be contributing to the antitumor activity of indol-3-carbinol and, therefore, being of clinical importance . As described, we also observed significantly stronger induction of CYP1A1 transcripts than CYP1B1 with black cohosh treatment.
CYP1A1 is known as the classical target of the aryl hydrocarbon receptor (AhR). Interestingly, the receptor has also been upregulated with our experiment. The AhR, upon binding of a ligand, forms a heterodimeric complex with ARNT (aryl hydrocarbon receptor nuclear translocator) which induces transactivation of the CYPs and other target genes via binding to xenobiotic response elements (XREs) in their promoter regions . Classical AhR ligands and, therefore, CYP1A1 inducers are hydrophobic and planar or coplanar molecules of polycyclic structure. Although the cycloartane-type triterpenoids do not satisfy these structural requirements, gene expression of CYP1A1 was not only induced in our experiments by black cohosh extract but also by the cycloartane aglycons (5.0 ± 1.7 fold, p < 0.01 and 12.2 ± 3.4 fold, p < 0.01) and, to a lower but statistically significant extent, by actein (2.1 ± 0.8, p < 0.05 and 2.0 ± 0.2, p < 0.01). CYP1B1 was also differentially expressed by the triterpenoids. The upregulation of CYP1A1 and CYP1B1 expression by extract and purified cycloartanes cannot be explained by AhR binding. Indeed, black cohosh extract and compounds did not show any AhR activity in a reporter gene assay  in rat hepatoma H4IIE cells [see Additional file 2]. These findings are in contradiction with previous experiments showing weak AhR binding and transactivation activity of black cohosh extracts. However, these experiments were carried out with high concentrations (up to 200 μg/ml) and did not include single compounds [20, 21]. The upregulation of CYP1A1 and CYP1B1 may be linked to activation of genes involved with hypoxic stress response, although the consequences of upregulated stress response appear somewhat contradictory. AhR and hypoxia-induced signal transduction are connected via ARNT, and AhR and HIF1α compete in binding to ARNT. Hypoxic conditions reportedly inhibited AhR-dependent gene expression , on the other hand, a connection between CYP1A1 induction and hypoxia-induced gene regulation in Caco2 cells has been found .
Besides CYP1A1 and CYP1B1, 11 other selected mRNAs representing all regulated functional categories were investigated by real-time RT-PCR to verify the microarray results and to investigate the effects of the cycloartane-type triterpenoids. Briefly, all genes were regulated by the triterpenoids in the same direction and to a fairly comparable extent than with the extract. Hence, we provide here first evidence that cycloartane glycosides as well as their aglycons, which are most likely formed in the intestine prior to absorption, are putative active principles in black cohosh.
In conclusion, the microarray investigation on black cohosh in MCF-7 breast cancer cells revealed several new interesting aspects. Gene expression "contra cell proliferation" and "pro apoptosis" emphasizes previously reported actions of black cohosh. These effects might be a result of stress response to hypoxic conditions, protein disturbances and induction of oxidoreductases, evoked by an exposure to black cohosh extract. Regulation of other genes, eg. induction of CYP1A1, IFNGR1 and WARS and downregulation of ERα mRNA (ESR1) might contribute to a putative antitumor activity of black cohosh. On the other hand, activation of genes involved in cell survival, angiogenesis and tumor progression, such as VEGF, S100P, MALAT-1 and different stress response genes, raises questions. Since black cohosh is increasingly popular as an alternative to HRT, a thorough benefit/risk assessment is required. Black cohosh preparations have been considered as safe up to now and no serious adverse reactions have been reported so far. Nonetheless, further investigations are needed to assess the safety level and to analyze putative antitumor applications with functional assays and in vivo models.
We are very grateful to Dr. Joachim Clement, Clinic of Internal Medicine II, University of Jena, Germany, for providing the MCF-7 cells and the LightCycler® PCR system, and to Prof. Dr. Dieter Schrenk, Annette Baumgart and Dr. Hans-Joachim Schmitz, Division of Food Chemistry/Toxicology, University of Kaiserslautern, Germany, for performing the AhR reporter gene assay.
- Liske E: Therapeutic efficacy and safety of Cimicifuga racemosa for gynecologic disorders. Adv Ther. 1998, 15: 45-53.PubMedGoogle Scholar
- Borrelli F, Ernst E: Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol. 2002, 58: 235-241. 10.1007/s00228-002-0457-2.View ArticlePubMedGoogle Scholar
- Mahady GB: Black cohosh (Actaea/Cimicifuga racemosa) – Review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol. 2005, 4: 177-184. 10.2165/00024677-200504030-00006.View ArticlePubMedGoogle Scholar
- Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.View ArticleGoogle Scholar
- Kruse SO, Lohning A, Pauli GF, Winterhoff H, Nahrstedt A: Fukiic and piscidic acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity of fukinolic acid. Planta Med. 1999, 65: 763-764. 10.1055/s-2006-960862.View ArticlePubMedGoogle Scholar
- Jarry H, Harnischfeger G: Endocrine effects of constituents of Cimicifuga racemosa: 1. The effect on serum levels of pituitary hormones in ovariectomized rats. Planta Med. 1985, 51: 46-49. 10.1055/s-2007-969390.View ArticlePubMedGoogle Scholar
- Jarry H, Harnischfeger G, Duker E: The endocrine effects of constituents of Cimicifuga racemosa: 2. In vitro binding of constituents to estrogen receptors. Planta Med. 1985, 51: 316-319. 10.1055/s-2007-969500.View ArticlePubMedGoogle Scholar
- Borrelli F, Izzo AA, Ernst E: Pharmacological effects of Cimicifuga racemosa. Life Sci. 2003, 73: 1215-1229. 10.1016/S0024-3205(03)00378-3.View ArticlePubMedGoogle Scholar
- Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K: Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. Maturitas. 1996, 25: 149-153. 10.1016/0378-5122(96)01052-3.View ArticlePubMedGoogle Scholar
- Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, Farnsworth NR, Bolton JL: Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem. 2001, 49: 2472-2479. 10.1021/jf0014157.View ArticlePubMedGoogle Scholar
- Stromeier S, Petereit F, Nahrstedt A: Phenolic esters from the rhizomes of Cimicifuga racemosa do not cause proliferation effects in MCF-7 cells. Planta Med. 2005, 71: 495-500. 10.1055/s-2005-864148.View ArticlePubMedGoogle Scholar
- Bodinet C, Freudenstein J: Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat. 2002, 76: 1-10. 10.1023/A:1020241509382.View ArticlePubMedGoogle Scholar
- Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G: Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol. 2002, 80: 125-130. 10.1016/S0960-0760(01)00178-9.View ArticlePubMedGoogle Scholar
- Wuttke W, Seidlovα-Wuttke D, Gorkow C: The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: Effects on menopause symptoms and bone markers. Maturitas. 2003, 44: S67-S77. 10.1016/S0378-5122(02)00350-X.View ArticlePubMedGoogle Scholar
- Seidlovα-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, Wuttke W: Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: Comparison with estradiol-17beta. Eur J Endocrinol. 2003, 149: 351-362. 10.1530/eje.0.1490351.View ArticleGoogle Scholar
- Jarry H, Metten M, Spengler B, Christoffel V, Wuttke W: In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas. 2003, 44: S31-S38. 10.1016/S0378-5122(02)00346-8.View ArticlePubMedGoogle Scholar
- Viereck V, Emons G, Wuttke W: Black cohosh: just another phytoestrogen?. Trends Endocrinol Metab. 2005, 16: 214-221. 10.1016/j.tem.2005.05.002.View ArticlePubMedGoogle Scholar
- Zava DT, Dollbaum CM, Blen M: Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med. 1998, 217: 369-78.View ArticlePubMedGoogle Scholar
- Beck V, Unterrieder E, Krenn L, Kubelka W, Jungbauer A: Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol. 2003, 84: 259-268. 10.1016/S0960-0760(03)00034-7.View ArticlePubMedGoogle Scholar
- Jeuken A, Keser BJ, Khan E, Brouwer A, Koeman J, Denison MS: Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits. J Agric Food Chem. 2003, 51: 5478-5487. 10.1021/jf030252u.View ArticlePubMedGoogle Scholar
- Jarry H, Thelen P, Christoffel V, Spengler B, Wuttke W: Cimicifuga racemosa extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP. Phytomedicine. 2005, 12: 178-182. 10.1016/j.phymed.2004.02.006.View ArticlePubMedGoogle Scholar
- Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R: Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat. 2004, 84: 151-160. 10.1023/B:BREA.0000018413.98636.80.View ArticlePubMedGoogle Scholar
- Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R: Evaluation of cell death caused by triterpene glycosides and phenolic substances from Cimicifuga racemosa extract in human MCF-7 breast cancer cells. Biol Pharm Bull. 2004, 27: 1970-1975. 10.1248/bpb.27.1970.View ArticlePubMedGoogle Scholar
- Einbond LS, Shimizu M, Xiao D, Nuntanakorn P, Lim JT, Suzui M, Seter C, Pertel T, Kennelly EJ, Kronenberg F, Weinstein IB: Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells. Breast Cancer Res Treat. 2004, 83: 221-231. 10.1023/B:BREA.0000014043.56230.a3.View ArticlePubMedGoogle Scholar
- Lohning A, Verspohl EJ, Winterhoff H: Pharmacological studies on the dopaminergic activity of Cimicifuga racemosa. Paper presented at the 23rd Int LOF-Symposium on Phytoestrogens, University of Gent, Belgium 15th January 1999Google Scholar
- Burdette JE, Liu J, Chen SN, Fabricant DS, Piersen CE, Barker EL, Pezzuto JM, Mesecar A, Van Breemen RB, Farnsworth NR, Bolton JL: Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003, 51: 5661-5670. 10.1021/jf034264r.View ArticlePubMedGoogle Scholar
- Fabricant DS, Nikolic D, Lankin DC, Chen SN, Jaki BU, Krunic A, van Breemen RB, Fong HH, Farnsworth NR, Pauli GF: Cimipronidine, a cyclic guanidine alkaloid from Cimicifuga racemosa. J Nat Prod. 2005, 68: 1266-1270. 10.1021/np050066d.View ArticlePubMedGoogle Scholar
- Rhyu MR, Lu J, Webster DE, Fabricant DS, Farnsworth NR, Wang ZJ: Black cohosh (Actaea racemosa, Cimicifuga racemosa) behaves as a mixed competitive ligand and partial agonist at the human μ opiate receptor. J Agric Food Chem. 2006, 54: 9852-9857. 10.1021/jf062808u.PubMed CentralView ArticlePubMedGoogle Scholar
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4.View ArticleGoogle Scholar
- Denizot F, Lang R: Rapid colorimetric assay for cellular growth and survival: Modifications to the tetrazolium dye procedure giving improved sensivity and reliability. J Immunol Meth. 1986, 89: 271-277. 10.1016/0022-1759(86)90368-6.View ArticleGoogle Scholar
- RMAExpress, release 0.5. [http://rmaexpress.bmbolstad.com]
- Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics. 2003, 19: 185-193. 10.1093/bioinformatics/19.2.185.View ArticlePubMedGoogle Scholar
- Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31: e15-10.1093/nar/gng015.PubMed CentralView ArticlePubMedGoogle Scholar
- Villalobos M, Olea N, Brotons JA, Olea-Serrano MF, Ruiz de Almodovar JM, Pedraza V: The E-screen assay: a comparison of different MCF7 cell stocks. Environ Health Perspect. 1995, 103: 844-850. 10.2307/3432398.PubMed CentralView ArticlePubMedGoogle Scholar
- Tian CY, Hu CQ, Xu G, Song HY: Assessment of estrogenic activity of natural compounds using improved E-screen assay. Acta Pharmacol Sin. 2002, 23: 572-576.PubMedGoogle Scholar
- NetAffx™ Analysis Center. [http://www.affymetrix.com/analysis/index.affx]
- Gene Expression Omnibus. [http://www.ncbi.nlm.nih.gov/geo/]
- GenMAPP. [http://www.genmapp.org]
- Wakasugi K, Schimmel P: Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science. 1999, 284: 147-151. 10.1126/science.284.5411.147.View ArticlePubMedGoogle Scholar
- Raabe EH, Abdurrahman L, Behbehani G, Arceci RJ: An SNF2 factor involved in mammalian development and cellular proliferation. Dev Dyn. 2001, 221: 92-105. 10.1002/dvdy.1128.View ArticlePubMedGoogle Scholar
- Ron D: Translational control in the endoplasmic reticulum stress response. J Clin Invest. 2002, 110: 1383-1388. 10.1172/JCI200216784.PubMed CentralView ArticlePubMedGoogle Scholar
- Sun S, Han J, Ralph WM, Chandrasekaran A, Liu K, Auborn KJ, Carter TH: Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. Cell Stress Chaperones. 2004, 9: 76-87.PubMed CentralView ArticlePubMedGoogle Scholar
- Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, Kalinski H, Kamer I, Rozen A, Mor O, Keshet E, Leshkowitz D, Einat P, Skaliter R, Feinstein E: Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol. 2002, 22: 2283-2293. 10.1128/MCB.22.7.2283-2293.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu MX: Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. Apoptosis. 2003, 8: 11-18. 10.1023/A:1021688600370.View ArticlePubMedGoogle Scholar
- Path G, Opel A, Knoll A, Seufert J: Nuclear protein p8 is associated with glucose-induced pancreatic beta-cell growth. Diabetes. 2004, 53: S82-85. 10.2337/diabetes.53.2007.S82.View ArticlePubMedGoogle Scholar
- Ito Y, Yoshida H, Motoo Y, Iovanna JL, Nakamura Y, Kakudo K, Uruno T, Takamura Y, Miya A, Noguchi S, Kuma K, Miyauchi A: Expression of p8 protein in breast carcinoma: an inverse relationship with apoptosis. Anticancer Res. 2005, 25: 833-837.PubMedGoogle Scholar
- Harris AL: Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2: 38-47. 10.1038/nrc704.View ArticlePubMedGoogle Scholar
- Patil C, Walter P: Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. Curr Opin Cell Biol. 2001, 13: 349-355. 10.1016/S0955-0674(00)00219-2.View ArticlePubMedGoogle Scholar
- Feldman DE, Chauhan V, Koong AC: The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res. 2005, 3: 597-605. 10.1158/1541-7786.MCR-05-0221.View ArticlePubMedGoogle Scholar
- Watowich SS, Morimoto RI: Complex regulation of heat shock- and glucose-responsive genes in human cells. Mol Cell Biol. 1988, 8: 393-405.PubMed CentralView ArticlePubMedGoogle Scholar
- Fafournoux P, Bruhat A, Jousse C: Amino acid regulation of gene expression. Biochem J. 2000, 351: 1-12. 10.1042/0264-6021:3510001.PubMed CentralView ArticlePubMedGoogle Scholar
- Wouters BG, van den Beucken T, Magagnin MG, Koritzinsky M, Fels D, Koumenis C: Control of the hypoxic response through regulation of mRNA translation. Semin Cell Dev Biol. 2005, 16: 487-501. 10.1016/j.semcdb.2005.03.009.View ArticlePubMedGoogle Scholar
- Cummins EP, Taylor CT: Hypoxia-responsive transcription factors. Pfluegers Arch Eur J Physiol. 2005, 450: 363-371. 10.1007/s00424-005-1413-7.View ArticleGoogle Scholar
- Budanov AV, Shoshani T, Faerman A, Zelin E, Kamer I, Kalinski H, Gorodin S, Fishman A, Chajut A, Einat P, Skaliter R, Gudkov AV, Chumakov PM, Feinstein E: Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene. 2002, 21: 6017-6031. 10.1038/sj.onc.1205877.View ArticlePubMedGoogle Scholar
- Kim R, Emi M, Tanabe K, Murakami S: Role of the unfolded protein response in cell death. Apoptosis. 2006, 11: 5-13. 10.1007/s10495-005-3088-0.View ArticlePubMedGoogle Scholar
- Kokame K, Agarwala KL, Kato H, Miyata T: Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress. J Biol Chem. 2000, 275: 32846-32853. 10.1074/jbc.M002063200.View ArticlePubMedGoogle Scholar
- Kurebayashi J, Otsuki T, Moriya T, Sonoo H: Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res. 2001, 92: 1093-1101.View ArticlePubMedGoogle Scholar
- Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13: 95-109. 10.1016/S1359-6101(01)00038-7.View ArticlePubMedGoogle Scholar
- Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Muller-Tidow C: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003, 22: 8031-8041. 10.1038/sj.onc.1206928.View ArticlePubMedGoogle Scholar
- Russo J, Hu YF, Silva ID, Russo IH: Cancer risk related to mammary gland structure and development. Microsc Res Tech. 2001, 52: 204-223. 10.1002/1097-0029(20010115)52:2<204::AID-JEMT1006>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Ko YG, Park H, Kim S: Novel regulatory interactions and activities of mammalian tRNA synthetases. Proteomics. 2002, 2: 1304-1310. 10.1002/1615-9861(200209)2:9<1304::AID-PROT1304>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
- Dalton TP, Puga A, Shertzer HG: Induction of cellular oxidative stress by aryl hydrocarbon receptor activation. Chem Biol Interact. 2002, 141: 77-95. 10.1016/S0009-2797(02)00067-4.View ArticlePubMedGoogle Scholar
- Delescluse C, Lemaire G, de Sousa G, Rahmani R: Is CYP1A1 induction always related to AHR signaling pathway?. Toxicology. 2001, 153: 73-82. 10.1016/S0300-483X(00)00305-X.View ArticleGoogle Scholar
- Baumgart A, Schmidt M, Schmitz HJ, Schrenk D: Natural furanocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes. Biochem Pharmacol. 69: 657-667. 10.1016/j.bcp.2004.11.017.Google Scholar
- Chan WK, Yao G, Gu YZ, Bradfield CA: Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation. J Biol Chem. 1999, 274: 12115-12123. 10.1074/jbc.274.17.12115.View ArticlePubMedGoogle Scholar
- Carriere V, Rodolosse A, Lacasa M, Cambier D, Zweibaum A, Rousset M: Hypoxia and CYP1A1 induction-dependent regulation of proteins involved in glucose utilization in Caco-2 cells. Am J Physiol. 1998, 274: G1101-1108.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.